<DOC>
	<DOCNO>NCT02912013</DOCNO>
	<brief_summary>The Mē Mini compact version Mē device clear FDA removal unwanted hair permanent hair reduction skin color ( Fitzpatrick skin photo-types I-VI ) base series multi-site clinical study . The purpose post-marketing study support claim removal unwanted hair permanent hair reduction compact version device .</brief_summary>
	<brief_title>The Efficacy Me Mini Device Hair Removal</brief_title>
	<detailed_description>The purpose post-marketing study determine efficacy mē mini hair removal device compare extent hair removal without maintenance treatment . Healthy female , dark hair treatment area desire remove hair enrol . Subjects provide device instruct method usage . The subject expect self-administer treatment clinic `` simulate home environment '' . Subjects receive 7 `` basic treatment '' weekly interval 3 additional maintenance treatment 1 side 1 month interval ( `` Maintenance '' v `` No maintenance '' side ) . In second phase study subject consent complete first phase offer option continue 9 additional maintenance treatment 1 month interval . Follow ups conduct 1 , 3 , 6 , 9 , 12 month last basic treatment . Evaluations include hair clearance , skin safety , tolerability procedure , subject , satisfaction .</detailed_description>
	<criteria>1 . Healthy male female , 18 65 year age . 2 . Subject Black dark brown terminal hair area treat . 3 . Terminal hair density requirement great 15 hair within hair count site ( 3x3 cm area ) determine manual hair count perform study investigator . 4 . Willing sign inform consent . 5 . Willing follow treatment schedule post treatment followup . 6 . Willingness photograph treat area take may use marketing educational presentation and/or publication willing sign photorelease form . 7 . Willingness avoid excessive sun exposure two week prior treatment Skin Hair 1 . Subjects white , red , light brown and/ blonde hair area treat . 2 . A history keloidal scarring ( hypertrophic scar keloid ) . 3 . Active dermatologic lesion infection treatment site . 4 . Subject permanent tattoo makeup treatment area . 5 . Recently tan area treat and/or unable unlikely refrain tan study . 6 . Subject disease related photosensitivity , porphyria , polymorphic light eruption , solar urticaria , lupus , etc 7 . Subject history herpes outbreak area treatment , unless receive preventative treatment physician Other Medical Conditions 8 . Pregnant , plan become pregnant , hormone fluctuation and/or breast feeding experiment . 9 . Subjects Diabetes ( Type I II ) systemic metabolic condition 10 . Subject active electrical implant anywhere body , pacemaker , internal defibrillator , insulin pump , incontinence device , etc . 11 . Subject suffers epilepsy . 12 . Subject active cancer , history skin cancer cancer area treat , include presence malignant premalignant pigment lesion . 13 . Subject receive radiation therapy chemotherapy treatment past 3 month . 14 . Subject know anticoagulative thromboembolic condition form anticoagulation treatment . 15 . Subject history immunosuppressant/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication . 16 . Subject condition physician 's opinion would make unsafe subject treat . Medication/treatments 17 . Subject rotate type tweezer epilator treatment , wax within last 3 month 18 . Subject electrolysis treatment within last 6 month treatment area . 19 . Subject type professional intense pulse light ( IPL ) , laser RF hair removal treatment site within last 6 month . 20 . Subject take medication know induce photosensitivity , include nonsteroidal antiinflammatory agent , tetracycline , phenothiazine , thiazide diuretic , sulfonylurea , sulfonamide , Dacarbazine ( DTIC ) , fluorouracil , vinblastine , griseofulvin within 4 week therapy . 21 . Subject take Accutane® within 6 month therapy . 22 . Subject steroid regimen last three month . 23 . Subject Gold therapy ( arthritis treatment ) . 24 . Subjects participate clinical study within 30 day prior first plan treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>